A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19
Status:
Completed
Trial end date:
2020-08-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and tolerability of LY3819253 when it is
given by injection into a vein to participants hospitalized with COVID-19. Blood tests will
be done to check how much LY3819253 is in the bloodstream and how long the body takes to
eliminate it. Participation could last about 8 weeks and may include up to 15 visits in the
hospital or the home.